Quantum BioPharma Ltd. logo

Quantum BioPharma Ltd.(NASDAQ) QNTM

Market Cap$23.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-97%
1 Year-81%
1 Month-10%
$2.69
-6.92%
-0.20Today
After hours$2.68-$0.01 (-0.37%)
Quantum BioPharma Ltd. last closing stock price
MetricPriceDate
Last closeUSD 2.892026-10-13
Quantum BioPharma Ltd. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.47%USD 3.092026-10-06
1 month-9.69%USD 3.202026-09-11
3 month-15%USD 3.402026-07-15
Year to date-60.41%USD 7.302025-12-31
1 year-80.97%USD 15.192025-10-13
3 year-96.13%USD 74.752023-10-13
5 year-96.91%USD 93.602021-10-14
Since inception-99.73%USD 1,089.632018-06-11

Quantum BioPharma Ltd. Financials at a Glance

Market Cap

$23.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$24.89M

EPS (TTM)

-$5.69

P/E Ratio

-0.51

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$2.69

Volume

180,276

Open

$2.85

Previous Close

$2.66

Daily Range

$2.66 - $2.89

52-Week Range

$2.07 - $16.36

Estimated Earnings Date

Nov 6, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quantum BioPharma Ltd.

Quantum BioPharma Ltd. is a biopharmaceutical firm based in Toronto, Canada, focused on developing innovative solutions for complex neurodegenerative, inflammatory, and metabolic conditions. The company is advancing a diverse pipeline of drug candidates, including treatments for multiple sclerosis and alcohol use disorder.

Products and Services
  • Lucid-MS, a proprietary drug candidate in Phase 2 trials for multiple sclerosis
  • Therapeutic solutions targeting alcohol addiction for clinical environments
  • Strategic investment holdings in residential real estate
Growth Outlook
  • Pipeline includes promising candidates addressing significant unmet medical needs
  • Recent clinical trials show potential for Lucid-MS to reverse myelin degradation
  • Strategic investments provide additional revenue streams and financial stability
Financial Highlights
  • Recent quarterly net income of -$3.17 million, reflecting ongoing R&D investments
  • Cash and short-term investments totaled $9.73 million as of June 30, 2026
  • Market capitalization stands at approximately $23 million, indicating growth potential
Quantum BioPharma Ltd. is positioned in the biotechnology sector, focusing on innovative treatments for serious health conditions. The company's flagship asset, Lucid-MS, is currently undergoing clinical trials, with preclinical data suggesting its efficacy in addressing multiple sclerosis. Additionally, the development of a therapeutic solution for alcohol use disorder highlights the company's commitment to tackling pressing health issues. The financial landscape shows a focus on research and development, with significant investments aimed at advancing the drug pipeline. Despite recent net losses, the company maintains a solid cash position, which supports ongoing operations and future growth initiatives. The strategic investment portfolio further diversifies revenue sources, enhancing financial resilience. Overall, Quantum BioPharma Ltd. presents a compelling opportunity for investors interested in the biotechnology sector, particularly those looking for companies with innovative solutions and a strong commitment to addressing unmet medical needs.
AI Generated • Sep 22, 2026

Industry

Pharmaceuticals

Employees

7

CEO

Zeeshan Saeed

Headquarters

Toronto, ON M5C 2V9, CA

QNTM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-413.07%

Return on Capital

-174.19%

Return on Assets

-173.14%

Earnings Yield

-1.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$23.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.09M

Volume

180.28K

Avg. Volume

205.55K

Financials (TTM)

Gross Profit

-$250.78K

Operating Income

-$1.91M

EBITDA

-$23.66M

Operating Cash Flow

-$5.42M

Capital Expenditure

-$6.00

Free Cash Flow

-$5.42M

Cash & ST Invst.

$9.73M

Total Debt

$962.16K

Quantum BioPharma Ltd. Performance Analysis

Quantum BioPharma Ltd. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Quantum BioPharma Ltd. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Quantum BioPharma Ltd. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.61-39.6%
20232023-12-31USD -0.46-24.4%
20242024-12-31USD -12.492612.8%
20252025-12-31USD -7.97-36.2%
Quantum BioPharma Ltd. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3054.2%
Q42025-12-3143.6%
Q12026-03-31-277.2%
Q22026-06-3083.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$125.11K

N/A

Gross Margin

0.00%

N/A

Market Cap

$23.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.37M

N/A

Employees

17

N/A

Net Income

-$3.17M

+65.7%

EBITDA

-$2.12M

+77.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$9.73M

+536.9%

Total Debt

$962.16K

-57.5%

Accounts Receivable

$107.50K

-96.7%

Inventory

$52.95K

-31.1%

Long Term Debt

$0.00

N/A

Short Term Debt

$962.16K

-57.5%

Return on Assets

-1.73%

N/A

Return on Invested Capital

-31.43%

N/A

Free Cash Flow

-$1.74M

+10.5%

Operating Cash Flow

-$1.74M

+10.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EVAXEvaxion Biotech A/S
$2.80+1.45%
RMTIRockwell Medical, Inc.
$7.66-2.42%
RNTXRein Therapeutics Inc.
$0.59-22.34%
RVPHReviva Pharmaceuticals Holdings, Inc.
$0.48-3.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$51.39-4.76%
NVDANvidia
$221.30-3.16%
CRWVCoreWeave
$65.78-15.46%
INTCIntel
$98.12-4.56%

Questions About QNTM

What is the current price of Quantum BioPharma Ltd.?

Quantum BioPharma Ltd. is trading at $2.66 per share.

What is the 52-week range for Quantum BioPharma Ltd.?

Over the past 52 weeks, Quantum BioPharma Ltd. has traded between $2.07 and $16.36.

How much debt does Quantum BioPharma Ltd. have?

As of the most recent reporting period, Quantum BioPharma Ltd. reported total debt of $963.31K.

How much cash does Quantum BioPharma Ltd. have on hand?

Quantum BioPharma Ltd. reported $3.65M in cash and cash equivalents in its most recent financial results.

What is Quantum BioPharma Ltd.’s dividend yield?

Quantum BioPharma Ltd. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.